Banner - NPPA Connect

|Videos|July 20, 2023

Comparing Current Treatment Agents for AD

Author(s)Christopher G. Bunick, MD, PhD, Ruth Ann Vleugels, MD, MPH, MBA

Experts discuss a recent network meta-analysis comparing current monotherapies for atopic dermatitis (AD) and how this may change standards of care.

Episodes in this series

EP. 1 JAK Inhibitor Overview and Relevance to AD

EP. 1 JAK Inhibitor Overview and Relevance to AD

EP. 2 Comparing Current Treatment Agents for AD

EP. 2 Comparing Current Treatment Agents for AD

EP. 3 Clinical Experience With JAK Inhibitor in AD

EP. 3 Clinical Experience With JAK Inhibitor in AD

EP. 4 Experts Present Background on Long-Term Safety Study of Upadacitinib for AD

EP. 4 Experts Present Background on Long-Term Safety Study of Upadacitinib for AD

EP. 5 Experts on Results of Long-Term Safety Study of Upadacitinib for AD

EP. 5 Experts on Results of Long-Term Safety Study of Upadacitinib for AD

EP. 6 Conclusions of Study on Long-Term Safety Study of Upadacitinib for AD

EP. 6 Conclusions of Study on Long-Term Safety Study of Upadacitinib for AD

EP. 7 Assessing Risk Factors of Oral JAK Inhibitors and Traditional Agents

EP. 7 Assessing Risk Factors of Oral JAK Inhibitors and Traditional Agents

EP. 8 Experts Present Background on JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 8 Experts Present Background on JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 9 Experts on Results of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 9 Experts on Results of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 10 Visualizing Safety Rates: Drug Events, Disease Baseline, and General Population Baseline

EP. 10 Visualizing Safety Rates: Drug Events, Disease Baseline, and General Population Baseline

EP. 11 Box Warning and JAK Inhibitor

EP. 11 Box Warning and JAK Inhibitor

EP. 12 JAK Inhibitor Selectivity

EP. 12 JAK Inhibitor Selectivity

EP. 13 Conclusions of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 13 Conclusions of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP. 14 Evolving the Standard of Care for AD: Safety and Treatment Response

EP. 14 Evolving the Standard of Care for AD: Safety and Treatment Response

EP. 15 Transitioning Patients from Traditional Immunosuppressive Agents to JAK Inhibitor

EP. 15 Transitioning Patients from Traditional Immunosuppressive Agents to JAK Inhibitor

EP. 16 AD Endotypes and Outcomes

EP. 16 AD Endotypes and Outcomes

EP. 17 Final Thoughts on JAK Inhibitor for AD

EP. 17 Final Thoughts on JAK Inhibitor for AD

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Rezpegaldesleukin Improves Atopic Dermatitis in Phase 2b Trial

ByShannon Heaning, Content Associate

August 25th 2026

The Multibillion-Dollar Molecule: How Zumilokibart’s Phase 2 Success Sparked AbbVie’s Acquisition

ByMarie Bosslett, Assistant Editor

August 24th 2026

Lebrikizumab Pregnancy Study Opens for Atopic Dermatitis

ByShannon Heaning, Content Associate

August 20th 2026

GX-03 Cuts Itch-Related Cytokine IL-31 by Nearly 68% in AD Model

ByShannon Heaning, Content Associate

August 20th 2026

Skin & Psych: Using Habit Loop Science to Interrupt the Itch-Scratch Cycle

ByPatricia Delgado, DNP, AGPCNP, DCNP, PMHNP,Judson A. Brewer, MD, Ph.D.,Shannon Heaning, Content Associate

August 18th 2026

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

How Emerging Androgenetic Alopecia Therapies Target DHT at the Scalp Level

25 Years Later: Remembering September 11 Through the Lens of Dermatologic and Burn Care

Isotretinoin Use in Adolescence Not Linked to Reduced Adult Height

Dermatology Times Inaugural NP/PA Connect Cutaneous Oncology Workshop Kicks Off in Tampa

Ultrapulse CO2 Laser Therapy Shows Promise for Chronic Acne Conglobata Sequelae